Advanced

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.

Nordström, Lena; Sernbo, Sandra; Eden, Patrik; Grønbaek, Kirsten; Kolstad, Arne; Räty, Riikka; Karjalainen, Marja-Liisa; Geisler, Christian; Ralfkiaer, Elisabeth and Sundström, Christer, et al. (2014) In British Journal of Haematology 166(1). p.98-108
Abstract
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic... (More)
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Haematology
volume
166
issue
1
pages
98 - 108
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • pmid:24684350
  • wos:000339341700013
  • scopus:84902333158
ISSN
0007-1048
DOI
10.1111/bjh.12854
language
English
LU publication?
yes
id
ba6707ec-29d6-4d34-a8fc-77811fed5fea (old id 4431457)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24684350?dopt=Abstract
date added to LUP
2014-05-07 19:15:43
date last changed
2017-11-12 03:07:28
@article{ba6707ec-29d6-4d34-a8fc-77811fed5fea,
  abstract     = {Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.},
  author       = {Nordström, Lena and Sernbo, Sandra and Eden, Patrik and Grønbaek, Kirsten and Kolstad, Arne and Räty, Riikka and Karjalainen, Marja-Liisa and Geisler, Christian and Ralfkiaer, Elisabeth and Sundström, Christer and Laurell, Anna and Delabie, Jan and Ehinger, Mats and Jerkeman, Mats and Ek, Sara},
  issn         = {0007-1048},
  language     = {eng},
  number       = {1},
  pages        = {98--108},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.},
  url          = {http://dx.doi.org/10.1111/bjh.12854},
  volume       = {166},
  year         = {2014},
}